EpicGenetics Announces 50 Percent Increase in Fibromyalgia FM/a® Test Requests Since September
EpicGenetics, the biomedical company that developed and offers the FM/a Test, the FDA-compliant diagnostic blood test that identifies the immune system biomarkers of fibromyalgia, today announced a 50 percent growth in applications for the test.
In September, the U.S. Food and Drug Administration (FDA) approved the Massachusetts General Hospital for a human clinical trial of BCG (an inexpensive generic vaccine used globally to prevent tuberculosis) to treat and reverse the biology of fibromyalgia. The announcement sparked the interest of many fibromyalgia patients.
“I regularly hear from patients who are thankful for a test that legitimizes their disease and saves them the time and money of the traditional ‘rule out’ method,” said Bruce Gillis, M.D., CEO of EpicGenetics. “Patients are mobilizing because now, for the first time, there is hope. They have the chance of a treatment that does more than merely mask the symptoms. It actually addresses the disease of fibromyalgia.”
Patients who want to be eligible to participate are urged to contact EpicGenetics to get the test and requirement information at https://fmtest.com/.
Dr. Gillis has been an advocate for fibromyalgia patients since he and his research team at the University of Illinois, College of Medicine at Chicago discovered unique immune system, cellular and protein abnormalities which are associated with the disease of fibromyalgia six years ago.
EpicGenetics, Inc. is a privately held biomedical company based in Los Angeles, California, that developed and manufactures the FM/a® Test. EpicGenetics is dedicated to improving the diagnosis and treatment of fibromyalgia by offering the first conclusive diagnostic test for fibromyalgia, and by investing in and developing further comprehensive clinical studies at leading medical research centers. More information is available at www.FMTest.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005117/en/